Precision BioSciences Raises $110M to Advance ARCUS Genome Editing Programs Privately-held, Durham-Based Biotechnology Company Adds Leading Institutional Investors in a Series B Financing DURHAM, N. Car., June 26, 2018-- Precision BioSciences today announced the closing of an oversubscribed $110M Series B financing to further product development efforts based on its ARCUS® genome editing platform.